Critical Role of SREBP-1c Large-VLDL Pathway in Environment-Induced Hypertriglyceridemia of Apo AV Deficiency
暂无分享,去创建一个
Takeshi Kimura | T. Kadowaki | T. Yamauchi | S. Ishibashi | G. Liang | H. Okazaki | Y. Iizuka | T. Gotoda | H. Yagyu | Yuichi Ikeda | Ako Matsuhashi | Manabu Takahashi | H. Kumagai | Sachiko Okazaki | Mikio Takanashi | Chengcheng Li | Masaki Tanaka | Hiroki Yoshida | Akari Noda | Pengfei Xu | Satoru Takase
[1] M. Nagano,et al. A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration Published, JLR Papers in Press, June 16, 2005. DOI 10.1194/jlr.D500018-JLR200 , 2005, Journal of Lipid Research.
[2] Päivi Pajukanta,et al. Association of the APOLIPOPROTEIN A1/C3/A4/A5 Gene Cluster With Triglyceride Levels and LDL Particle Size in Familial Combined Hyperlipidemia , 2004, Circulation research.
[3] Toshiko Tanaka,et al. Two independent apolipoprotein A5 haplotypes modulate postprandial lipoprotein metabolism in a healthy Caucasian population. , 2007, The Journal of clinical endocrinology and metabolism.
[4] J. Goldstein,et al. Selective versus total insulin resistance: a pathogenic paradox. , 2008, Cell metabolism.
[5] S. Young,et al. Intravenous Injection of Apolipoprotein A-V Reconstituted High-Density Lipoprotein Decreases Hypertriglyceridemia in apoav−/− Mice and Requires Glycosylphosphatidylinositol-Anchored High-Density Lipoprotein–Binding Protein 1 , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[6] D. Steinberg,et al. Dissociation of apoprotein B and triglyceride production in very-low-density lipoproteins. , 1980, The American journal of physiology.
[7] P. Nilsson-ehle,et al. A stable, radioactive substrate emulsion for assay of lipoprotein lipase. , 1976, Journal of lipid research.
[8] G. S. Shelness,et al. Biogenesis of apolipoprotein A-V and its impact on VLDL triglyceride secretion[S] , 2011, Journal of Lipid Research.
[9] Tanya M. Teslovich,et al. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease , 2017, The New England journal of medicine.
[10] Y. Yazaki,et al. Heterogeneous mutations in the human lipoprotein lipase gene in patients with familial lipoprotein lipase deficiency. , 1991, The Journal of clinical investigation.
[11] S. Young,et al. The Acidic Domain of GPIHBP1 Is Important for the Binding of Lipoprotein Lipase and Chylomicrons* , 2008, Journal of Biological Chemistry.
[12] J. H. Lee,et al. Comparison of Low-Fat Meal and High-Fat Meal on Postprandial Lipemic Response in Non-Obese Men according to the −1131T>C Polymorphism of the Apolipoprotein A5 (APOA5) Gene (Randomized Cross-Over Design) , 2006, Journal of the American College of Nutrition.
[13] P. Pajukanta,et al. Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia , 2007, Nature Genetics.
[14] Martin Adiels,et al. Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[15] T. Kadowaki,et al. Identification of Neutral Cholesterol Ester Hydrolase, a Key Enzyme Removing Cholesterol from Macrophages* , 2008, Journal of Biological Chemistry.
[16] M. Brown,et al. Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. , 1999, The Journal of clinical investigation.
[17] J. Esko,et al. Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans. , 2013, The Journal of clinical investigation.
[18] Jonathan C. Cohen,et al. An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing , 2001, Science.
[19] R. Hammer,et al. Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice[S] , 2018, Journal of Lipid Research.
[20] S. Young,et al. Abnormal Patterns of Lipoprotein Lipase Release into the Plasma in GPIHBP1-deficient Mice* , 2008, Journal of Biological Chemistry.
[21] P. Reitsma,et al. Apolipoprotein A-V , 2001, The Journal of Biological Chemistry.
[22] A. Khera,et al. Genetics of coronary artery disease: discovery, biology and clinical translation , 2017, Nature Reviews Genetics.
[23] R. Zechner,et al. Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. , 1995, The Journal of clinical investigation.
[24] I. Sakata,et al. Role of Hormone-sensitive Lipase in Leptin-Promoted Fat Loss and Glucose Lowering , 2017, Journal of atherosclerosis and thrombosis.
[25] S. Grundy,et al. Dual defect in metabolism of very-low-density lipoprotein triglycerides. Patients with type 5 hyperlipoproteinemia. , 1984, JAMA.
[26] J. Heeren,et al. Give me A5 for lipoprotein hydrolysis! , 2005, The Journal of clinical investigation.
[27] J. Polonovski,et al. [Structure and metabolism of plasma lipoproteins]. , 1983, Pathologie-biologie.
[28] L. Pennacchio,et al. Apolipoprotein A-V Deficiency Results in Marked Hypertriglyceridemia Attributable to Decreased Lipolysis of Triglyceride-Rich Lipoproteins and Removal of Their Remnants , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[29] R. Hammer,et al. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. , 1998, The Journal of clinical investigation.
[30] Folkert Kuipers,et al. Stimulation of Lipogenesis by Pharmacological Activation of the Liver X Receptor Leads to Production of Large, Triglyceride-rich Very Low Density Lipoprotein Particles* , 2002, The Journal of Biological Chemistry.
[31] B. Staels,et al. Atheroprotective Effect of Human Apolipoprotein A5 in a Mouse Model of Mixed Dyslipidemia , 2008, Circulation research.
[32] M. Foretz,et al. Sterol-regulatory-element-binding protein 1c mediates insulin action on hepatic gene expression. , 2001, Biochemical Society transactions.
[33] Andrew D. Johnson,et al. Multiple rare alleles at LDLR and APOA5 confer risk for early-onset myocardial infarction , 2014, Nature.
[34] L. Pennacchio,et al. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. , 2005, The Journal of clinical investigation.
[35] D. Porte,et al. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. , 1973, The Journal of clinical investigation.
[36] R. Hammer,et al. Diminished Hepatic Response to Fasting/Refeeding and Liver X Receptor Agonists in Mice with Selective Deficiency of Sterol Regulatory Element-binding Protein-1c* , 2002, The Journal of Biological Chemistry.
[37] A. Cantafora,et al. Inherited Apolipoprotein A-V Deficiency in Severe Hypertriglyceridemia , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[38] A. Boodhoo,et al. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. , 2005, Clinical chemistry.
[39] K. Wenner,et al. Homozygosity for a partial deletion of apoprotein A-V signal peptide results in intracellular missorting of the protein and chylomicronemia in a breast-fed infant. , 2014, Atherosclerosis.
[40] Rick B. Vega,et al. CAT‐2003: A novel sterol regulatory element‐binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3‐Leiden mice , 2017, Hepatology communications.
[41] H. Sone,et al. Insulin-independent induction of sterol regulatory element-binding protein-1c expression in the livers of streptozotocin-treated mice. , 2004, Diabetes.
[42] B. Nordestgaard. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. , 2016, Circulation research.
[43] S. Nilsson,et al. Apolipoprotein A-V-heparin Interactions , 2005, Journal of Biological Chemistry.
[44] M. S. Brown,et al. Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[45] S. Yamashita,et al. Identification of Unique Lipoprotein Subclasses for Visceral Obesity by Component Analysis of Cholesterol Profile in High-Performance Liquid Chromatography , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[46] Päivi Pajukanta,et al. Association of the APOLIPOPROTEIN A 1 / C 3 / A 4 / A 5 Gene Cluster With Triglyceride Levels and LDL Particle Size in Familial Combined Hyperlipidemia , 2004 .
[47] Robert V Farese,et al. Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. , 2012, Cell metabolism.
[48] T. Kadowaki,et al. Increased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liver Published, JLR Papers in Press, June 1, 2006. , 2006, Journal of Lipid Research.
[49] K. Adeli,et al. Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome. , 2010, American journal of physiology. Endocrinology and metabolism.
[50] R. Hegele,et al. Chylomicronaemia—current diagnosis and future therapies , 2015, Nature Reviews Endocrinology.
[51] A. Remaley,et al. Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide , 2016, The Journal of Pharmacology and Experimental Therapeutics.
[52] J. Danesh,et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies , 2010, The Lancet.
[53] S. Young,et al. Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. , 2007, Cell metabolism.
[54] D. Nickerson,et al. Association of apolipoprotein A5 variants with LDL particle size and triglyceride in Japanese Americans. , 2004, Biochimica et biophysica acta.
[55] R. Krauss,et al. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. , 1993, The Journal of clinical investigation.
[56] P. Talmud. Rare APOA5 mutations--clinical consequences, metabolic and functional effects: an ENID review. , 2007, Atherosclerosis.
[57] T. Forte,et al. Apolipoprotein A-V gene therapy for disease prevention / treatment: a critical analysis , 2015, Journal of biomedical research.
[58] L. Pennacchio,et al. Apolipoprotein AV Accelerates Plasma Hydrolysis of Triglyceriderich Lipoproteins by Interaction with Proteoglycan-bound Lipoprotein Lipase* , 2005, Journal of Biological Chemistry.
[59] Joseph L Goldstein,et al. LXR-SREBP-1c-Phospholipid Transfer Protein Axis Controls Very Low Density Lipoprotein (VLDL) Particle Size* , 2009, The Journal of Biological Chemistry.
[60] Exome sequencing identifies rare LDLR and APOA 5 alleles conferring risk for myocardial infarction , 2016 .
[61] T. Forte,et al. Effect of apolipoprotein A-V on plasma triglyceride, lipoprotein size, and composition in genetically engineered mice Published, JLR Papers in Press, December 3, 2007. , 2008, Journal of Lipid Research.